This is a review about Smad4, based on 21 published articles (read how Labome selects the articles), using Smad4 antibody in all methods. It is aimed to help Labome visitors find the most suited Smad4 antibody.
Smad4 synonym: DPC4; JIP; MADH4; MYHRS; MAD homolog 4; SMAD, mothers against DPP homolog 4; deleted in pancreatic carcinoma locus 4; deletion target in pancreatic carcinoma 4; mothers against decapentaplegic homolog 4; mothers against decapentaplegic, Drosophila, homolog of, 4

Santa Cruz BiotechnologySanta Cruz Biotechnology Smad4 product
  • ChIP assayIn 2008, Sylvie Thuault et al. applied Santa Cruz Biotechnology Smad4 antibody to carry out Chromatin immunoprecipitation assays in order to investigate the roles for HMGA2 and Smads in the regulation of SNAIL1 expression during epithelial-mesenchymal transition [ncbi , more ]. In 2005, Che Chang Chang et al. utilized Santa Cruz Biotechnology Smad4 antibody to study transcriptional repression of smad4 [ncbi , more ].
  • immunohistochemistryChunming Dong et al. utilized Santa Cruz Biotechnology Smad4 antibody to demonstrate that alterations in the Smad pathway is responsible for TGF-beta hyperresponsiveness [ncbi , more ] in 2002 and Wen Xie et al. used Santa Cruz Biotechnology Smad4 antibody to address whether and how TGF-beta signaling becomes disrupted during human breast cancer development in vivo [ncbi , more ].
  • immunoprecipitationIn 2005, Che Chang Chang et al. utilized Santa Cruz Biotechnology Smad4 antibody to study transcriptional repression of smad4 [ncbi , more ]. In 2003, Xia Lin et al. employed Santa Cruz Biotechnology Smad4 antibody to study the activation of transforming growth factor-beta signaling by SUMO-1 modification of tumor suppressor Smad4/DPC4 [ncbi , more ]. In 2002, Ya Chung Tian et al. employed Santa Cruz Biotechnology Smad4 antibody to examine the influence of transforming growth factor (TGF) 1 on proximal tubular epithelial cell-cell interaction, with particular emphasis on the regulation of adherens junction complex formation [ncbi , more ].
  • western blotDavid J Shields et al. utilized Santa Cruz Biotechnology Smad4 antibody to perform western blot in order to study the roles of RBBP9 as a tumor-associated serine hydrolase to pancreatic neoplasia [ncbi , more ] in 2010 and Shinako Araki et al. used Santa Cruz Biotechnology Smad4 antibody to investigate the role of TGFB1 in the regulation of Mdm2 expression and late-stage breast cancer metastasis [ncbi , more ]. Blanca Herrera et al. used Santa Cruz Biotechnology Smad4 antibody to investigate the role of BMP9 signalling via ALK2/Smad1/Smad4 pathway in ovarian cancer [ncbi , more ] in 2009 and Lihua Ding et al. used Santa Cruz Biotechnology Smad4 antibody to study the suppressing role of human FHL1 family members in the modulation of tumor cell growth through a TGF-beta like signaling pathway [ncbi , more ]. In 2008, Miguel A Alejandre-Alcázar et al. utilized Santa Cruz Biotechnology Smad4 antibody to perform western blot in order to study the dynamical regulation of TGF-beta signaling during late lung development in the human and mouse [ncbi , more ]. In 2006, Anna Sergeeva et al. employed Santa Cruz Biotechnology Smad4 antibody to perform western blot assays in order to investigate the molecular regulation mechanisms of Smad4 in the process of normal pancreas development and pancreatic ductal adenocarcinomas (PDAC) growth (catalog: sc-7966) [ncbi , more ]. Nichole Boyer Arnold et al. applied Santa Cruz Biotechnology Smad4 antibody to study COLO-357 cell growth inhibition by TGF beta1 [ncbi , more ] in 2005 and Che Chang Chang et al. used Santa Cruz Biotechnology Smad4 antibody to study transcriptional repression of smad4 [ncbi , more ]. Yoshihide Asano et al. utilized Santa Cruz Biotechnology Smad4 antibody to study the impaired Smad7-Smurf mediated negative regulation of TGF- signaling in scleroderma fibroblasts [ncbi , more ] in 2004 and Michael B Major et al. used Santa Cruz Biotechnology Smad4 antibody to study the effect of gadd45beta3' enhancer on SMAD3- and SMAD4-dependent transcriptional induction by transforming growth factor beta (catalog: sc-7966) [ncbi , more ]. In 2003, Pierre S W Lee et al. applied Santa Cruz Biotechnology Smad4 antibody to study the role of Smad4 sumoylation in the regulation of TGF-beta signaling through Smads (catalog: sc-7154) [ncbi , more ]. Santa Cruz Biotechnology Smad4 antibody was utilized in 2002 to address whether and how TGF-beta signaling becomes disrupted during human breast cancer development in vivo [ncbi , more ], to detect Smad4 in human HT29 colon carcinoma sublines U9, HD3, and HD6, and human SW480 and SKCO-1 colon carcinoma cells [ncbi , more ]and to study the involvement of Smad proteins in the TGF-beta control of BGN and SLRP gene expression [ncbi , more ].
Cell Signaling TechnologyCell Signaling Technology Smad4 product
  • western blotIn 2009, Elspeth Gold et al. utilized Cell Signaling Technology Smad4 antibody to test a hypothesis that activin C antagonizes the effects of activin A and its overexpression leads to pathologies [ncbi , more ].
EMD MilliporeEMD Millipore Smad4 product
  • immunoprecipitationIn 2003, Dirk Haller et al. used EMD Millipore Smad4 antibody to study that transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation [ncbi , more ]. In 2002, Susan Fanayan et al. used EMD Millipore Smad4 antibody to study a signaling pathway for IGFBP-3 from a cell surface receptor to nuclear transcriptional activity [ncbi , more ].
  • western blotIn 2003, Dirk Haller et al. used EMD Millipore Smad4 antibody to study that transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation [ncbi , more ]. In 2002, Susan Fanayan et al. used EMD Millipore Smad4 antibody to study a signaling pathway for IGFBP-3 from a cell surface receptor to nuclear transcriptional activity [ncbi , more ].
Articles Reviewed
  1. David J Shields et al. (2010). "RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia".PMID 20080647
  2. Blanca Herrera et al. (2009). "Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation".PMID 19996292
  3. Shinako Araki et al. (2010). "TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer".PMID 19955655
  4. Lihua Ding et al. (2009). "Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway".PMID 19139564
  5. Elspeth Gold et al. (2009). "Activin C antagonizes activin A in vitro and overexpression leads to pathologies in vivo".PMID 19095948
  6. Sylvie Thuault et al. (2008). "HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition".PMID 18832382
  7. Miguel A Alejandre-Alcázar et al. (2008). "TGF-beta signaling is dynamically regulated during the alveolarization of rodent and human lungs".PMID 18095342
  8. Anna Sergeeva et al. (2006). "Display technologies: application for the discovery of drug and gene delivery agents".PMID 17123658
  9. Nichole Boyer Arnold et al. (2005). "Smad7 abrogates transforming growth factor-beta1-mediated growth inhibition in COLO-357 cells through functional inactivation of the retinoblastoma protein".PMID 15811853
  10. Che Chang Chang et al. (2005). "Daxx mediates the small ubiquitin-like modifier-dependent transcriptional repression of Smad4".PMID 15637079
  11. Yoshihide Asano et al. (2004). "Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts".PMID 14722617
  12. Michael B Major et al. (2004). "Identification of a gadd45beta 3' enhancer that mediates SMAD3- and SMAD4-dependent transcriptional induction by transforming growth factor beta".PMID 14630914
  13. Pierre S W Lee et al. (2003). "Sumoylation of Smad4, the common Smad mediator of transforming growth factor-beta family signaling".PMID 12740389
  14. Dirk Haller et al. (2003). "Transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation".PMID 12672795
  15. Xia Lin et al. (2003). "Activation of transforming growth factor-beta signaling by SUMO-1 modification of tumor suppressor Smad4/DPC4".PMID 12621041
  16. Wen Bin Chen et al. (2002). "Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells".PMID 12140283
  17. Ya Chung Tian et al. (2002). "Interaction between the transforming growth factor-beta type II receptor/Smad pathway and beta-catenin during transforming growth factor-beta1-mediated adherens junction disassembly".PMID 12000714
  18. Chunming Dong et al. (2002). "Deficient Smad7 expression: a putative molecular defect in scleroderma".PMID 11904440
  19. Wen Xie et al. (2002). "Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study".PMID 11809701
  20. Zhongfa Yan et al. (2002). "Transforming growth factor beta 1 induces proliferation in colon carcinoma cells by Ras-dependent, smad-independent down-regulation of p21cip1".PMID 11784716
  21. Susan Fanayan et al. (2002). "Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling".PMID 11751851